2021-10-01Zeitschriftenartikel
Emergence and spread of SARS-CoV-2 lineage B.1.620 with variant of concern-like mutations and deletions
Dudas, Gytis
Hong, Samuel L.
Potter, Barney I.
Calvignac-Spencer, Sébastien
Niatou-Singa, Frédéric S.
Tombolomako, Thais B.
Fuh-Neba, Terence
Vickos, Ulrich
Ulrich, Markus
Leendertz, Fabian H.
Khan, Kamran
Huber, Carmen
Watts, Alexander
Olendraitė, Ingrida
Snijder, Joost
Wijnant, Kim N.
Bonvin, Alexandre M.J.J.
Martres, Pascale
Behillil, Sylvie
Ayouba, Ahidjo
Foudi-Maïdadi, Martin
Meta-Djomsi, Dowbiss
Gowde, Celestin
Butel, Christelle
Šimaitis, Aistis
Gabrielaitė, Miglė
Katėnaitė, Monika
Norvilas, Rimvydas
Raugaitė, Ligita
Koyaweda, Giscard Wilfried
Kandou, Jephté Kaleb
Jonikas, Rimvydas
Nasvytienė, Inga
Žemeckienė, Živilė
Gečys, Dovydas
Tamušauskaitė, Kamilė
Norkienė, Milda
Vasiliūnaitė, Emilija
Žiogienė, Danguolė
Timinskas, Albertas
Šukys, Marius
Šarauskas, Mantas
Alzbutas, Gediminas
Amuri Aziza, Adrienne
Lusamaki, Eddy Kinganda
Makangara Cigolo, Jean-Claude
Muyembe Mawete, Francisca
Lofiko, Emmanuel Lokilo
Mbala-Kingebeni, Placide
Muyembe-Tamfum, Jean-Jacques
Belizaire, Marie Roseline Darnycka
Essomba, René Ghislain
Okomo Assoumou, Marie Claire
Mboringong, Akenji Blaise
Dieng, Alle Baba
Jouzapaitė, Dovilė
Hosch, Salome
Obama, Justino
Ondo'o Ayekaba, Mitoha
Naumovas, Daniel
Pautienius, Arnoldas
Rafaï, Clotaire Donatien
Vitkauskienė, Astra
Ugenskienė, Rasa
Gedvilaitė, Alma
Čereškevičius, Darius
Lesauskaitė, Vaiva
Žemaitis, Lukas
Griškevičius, Laimonas
Baele, Guy
Distinct SARS-CoV-2 lineages, discovered through various genomic surveillance initiatives, have emerged during the pandemic following unprecedented reductions in worldwide human mobility. We here describe a SARS-CoV-2 lineage - designated B.1.620 - discovered in Lithuania and carrying many mutations and deletions in the spike protein shared with widespread variants of concern (VOCs), including E484K, S477N and deletions HV69Δ, Y144Δ, and LLA241/243Δ. As well as documenting the suite of mutations this lineage carries, we also describe its potential to be resistant to neutralising antibodies, accompanying travel histories for a subset of European cases, evidence of local B.1.620 transmission in Europe with a focus on Lithuania, and significance of its prevalence in Central Africa owing to recent genome sequencing efforts there. We make a case for its likely Central African origin using advanced phylogeographic inference methodologies incorporating recorded travel histories of infected travellers
Dateien zu dieser Publikation